HLA-L

Across TCGA pan-cancer cohorts, HLA-L RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of HLA-L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where HLA-L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HLA-L is over-expressed in tumor, although a few such as LUSC show the opposite, repressed pattern.

KIRC, HNSC, and COAD are the cancer types where HLA-L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HLA-L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+1.310	<.001	11	view →
HNSC	All	III,IV	+0.859	<.001	10	view →
COAD	All	All	+0.935	.010	4	view →
STAD	All	II,III,IV	+0.843	.004	4	view →
LUSC	Male	All	−0.633	<.001	4	view →
BRCA	All	All	+0.331	.003	4	view →
ESCA	All	II,III,IV	+1.335	.035	2	view →
CHOL	All	All	+0.955	.001	2	view →
KIRP	All	All	+0.596	.004	2	view →
LIHC	All	All	+0.398	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

HLA-L–KIRC

Open the KIRC breakdown →